Document is current
Any future updates will be listed below
-
Authors
Nozaki, Tomoya
Fujieda, Kumiko
Furuhashi, Kazuhiro
Shimamura, Yuko
Karasawa, Munetoshi
Koshi-Ito, Eri
Watanabe, Yu
Onogi, Chikao
Hattori, Keita
Kato, Akihisa
Matsumoto, Jun
Kawazoe, Tomohiro
Horinouchi, Asuka
Tanaka, Akihito
Kim, Hangsoo
Maeda, Kayaho
Matsuyama, Makoto
Yamahara, Kenichi
Maruyama, Shoichi
- License Information
-
More Information
Article History
Received: 26 October 2025
Accepted: 8 June 2026
First Online: 19 June 2026
Declarations
Ethics approval and consent to participate: All animal experimental protocols were conducted in accordance with the guidelines of the Institutional Animal Ethics Committee of Nagoya University Graduate School of Medicine, and were performed under the approved project titled “Amnion-derived cell therapy for kidney injury and autoimmune diseases in rats and mice” (Approval number: M230165, Date of approval: March 6, 2023). Written informed consent was obtained from all participants or their legally authorized representatives for the use of AMSCs. The study was approved by the Ethics Committee of Hyogo College of Medicine (Approval number: 0325, Date of approval: August 7, 2024) for the project titled “Preclinical study for development of therapies using human fetal-derived hematopoietic and mesenchymal stem cells.”
Consent for publication: Not applicable.
Competing interests: The authors declare no competing interests.
